• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Birch Pollen Allergy - Pipeline Review, H1 2013 - Product Image

Birch Pollen Allergy - Pipeline Review, H1 2013

  • ID: 2557642
  • May 2013
  • 40 pages
  • Global Markets Direct

Birch Pollen Allergy – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Birch Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy. Birch Pollen Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Birch Pollen Allergy.
- A review of the Birch Pollen Allergy products under development by companies and universities/research READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Birch Pollen Allergy Overview
Therapeutics Development
An Overview of Pipeline Products for Birch Pollen Allergy
Birch Pollen Allergy Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Birch Pollen Allergy Therapeutics – Products under Development by Companies
Companies Involved in Birch Pollen Allergy Therapeutics Development
ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Circassia Holdings Ltd.
ANERGIS SA
Biomay AG
Birch Pollen Allergy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Birch Pollen Allergoid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-0206st - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALK Birch Pollen Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Birch Pollen Allergen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BM-31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ToleroMune Birch Allergy T-Cell Vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AllerT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch Pollen Allergy Therapeutics – Drug Profile Updates
Birch Pollen Allergy Therapeutics – Discontinued Products
Birch Pollen Allergy Therapeutics - Dormant Products
Birch Pollen Allergy – Product Development Milestones
Featured News & Press Releases
Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment
Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen
Aug 31, 2010: Anergis's Ultra-Fast Treatment Against Birch Pollen Allergy Demonstrates Long Term Immunoregulatory Effect
Jul 17, 2009: Anergis Reports Encouraging Seasonal Clinical Results With Birch Pollen Allergy Drug Candidate AllerT
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Birch Pollen Allergy, H1 2013
Products under Development for Birch Pollen Allergy – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
ALK-Abello A/S, H1 2013
Allergopharma Joachim Ganzer KG, H1 2013
Circassia Holdings Ltd., H1 2013
ANERGIS SA, H1 2013
Biomay AG, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Birch Pollen Allergy Therapeutics – Drug Profile Updates
Birch Pollen Allergy Therapeutics – Discontinued Products
Birch Pollen Allergy Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Birch Pollen Allergy, H1 2013
Products under Development for Birch Pollen Allergy – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 23

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos